Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis

[1]  S. Metallo,et al.  Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm. , 2018, Journal of molecular biology.

[2]  K. Stegmaier,et al.  EWS–FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma , 2018, Nature.

[3]  R. Young,et al.  EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. , 2018, Cancer cell.

[4]  R. Roesler,et al.  Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma , 2018, bioRxiv.

[5]  T. Olencki,et al.  Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870) , 2017, Clinical Cancer Research.

[6]  S. Hamilton,et al.  Long-term Outcomes and Complications in Pediatric Ewing Sarcoma , 2017, American journal of clinical oncology.

[7]  L. Helman,et al.  A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS–FLI1 fusion transcript , 2017, Cancer Chemotherapy and Pharmacology.

[8]  Atul J. Butte,et al.  In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma , 2016, Oncotarget.

[9]  B. Schäfer,et al.  Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue* , 2016, The Journal of Biological Chemistry.

[10]  S. Frye,et al.  High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility , 2016, Proceedings of the National Academy of Sciences.

[11]  Xianqin Wang,et al.  The effect of MS-275 on CYP450 isoforms activity in rats by cocktail method. , 2015, International journal of clinical and experimental pathology.

[12]  S. Safe,et al.  Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species–Dependent Targeting of Specificity Protein Transcription Factors , 2015, Molecular Cancer Therapeutics.

[13]  Cathy H. Wu,et al.  Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing , 2015, Proceedings of the National Academy of Sciences.

[14]  Helen X. Chen,et al.  Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group , 2015, Pediatric blood & cancer.

[15]  Nathan C. Sheffield,et al.  Epigenome Mapping Reveals Distinct Modes of Gene Regulation and Widespread Enhancer Reprogramming by the Oncogenic Fusion Protein EWS-FLI1 , 2015, Cell reports.

[16]  J. Whelan,et al.  A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre‐treated Ewing sarcoma ISRCTN11631773 , 2015, Pediatric blood & cancer.

[17]  S. Keir,et al.  Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program , 2014, Clinical Cancer Research.

[18]  Shawn M. Gillespie,et al.  EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. , 2014, Cancer cell.

[19]  Lufeng Hu,et al.  Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats , 2014, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  H. Frangoul,et al.  Outcome for Children with Metastatic Solid Tumors over the Last Four Decades , 2014, PloS one.

[21]  Jenny C. Chang,et al.  Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells , 2014, Oncotarget.

[22]  U. Mony,et al.  Pre‐clinical efficacy of PU‐H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma , 2014, Molecular oncology.

[23]  T. Triche,et al.  Characterization and Drug Resistance Patterns of Ewing's Sarcoma Family Tumor Cell Lines , 2013, PloS one.

[24]  Bohuslav Melichar,et al.  Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  B. Barneda-Zahonero,et al.  Histone deacetylases and cancer , 2012, Molecular oncology.

[26]  J. Healey,et al.  Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Lisa M Harlan-Williams,et al.  BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation , 2012, Proceedings of the National Academy of Sciences.

[28]  S. Baruchel,et al.  A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. , 2012, European journal of cancer.

[29]  J. Herman,et al.  Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. , 2011, Cancer discovery.

[30]  Jeffrey Knipstein,et al.  Entinostat for treatment of solid tumors and hematologic malignancies , 2011, Expert opinion on investigational drugs.

[31]  Sandeep Jain,et al.  Chemotherapy in Ewing’s sarcoma , 2010, Indian journal of orthopaedics.

[32]  Naomi J Balamuth,et al.  Ewing's sarcoma. , 2010, The Lancet. Oncology.

[33]  A. Üren,et al.  Small molecule selected to disrupt oncogenic protein EWS-FLI1 interaction with RNA Helicase A inhibits Ewing's Sarcoma , 2009, Nature Medicine.

[34]  K. Stegmaier,et al.  Phase II study of intermediate‐dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology Group , 2009, Pediatric blood & cancer.

[35]  B. Lake,et al.  Induction of drug metabolism: species differences and toxicological relevance. , 2008, Toxicology.

[36]  O. Politz,et al.  MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. , 2007, The international journal of biochemistry & cell biology.

[37]  U. Völker,et al.  Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells , 2007, Journal of Cancer Research and Clinical Oncology.

[38]  E. Sausville,et al.  Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. , 2007, Blood.

[39]  P. Marks.  Thioredoxin in cancer--role of histone deacetylase inhibitors. , 2006, Seminars in cancer biology.

[40]  K. Camphausen,et al.  Inhibition of hsp90 compromises the DNA damage response to radiation. , 2006, Cancer research.

[41]  E. Sausville,et al.  Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor , 2006, Cancer Chemotherapy and Pharmacology.

[42]  Y. Iwamoto,et al.  Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors , 2005, International journal of cancer.

[43]  E. Sausville,et al.  Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  S. Bates,et al.  MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. , 2002, Cancer research.

[45]  Christopher T Denny,et al.  Biology of EWS/ETS fusions in Ewing's family tumors , 2001, Oncogene.

[46]  T. Tsuruo,et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Thompson,et al.  The FLI-1 and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities. , 1994, The Journal of biological chemistry.

[48]  C. Denny,et al.  Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[49]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.